New Launches Focus On Non-Coding RNAs and Chronic Kidney Disease

Two new biotech companies launched today: NextRNA to focus on non-coding RNA technology, and Pathalys, with a clinic-ready licensed compound and plans to enter Phase III trials.

Related Keywords

Japan ,Cambridge ,Cambridgeshire ,United Kingdom ,Pathalys Pharma ,Catalys Pacific ,Robert Langer ,Takeshi Takahashi ,Dominique Verhelle ,Marc Cohen ,Mahesh Krishnan ,Kenneth Anderson ,Juliaa Novia ,Neal Fowler ,Jay Shepard ,Davita Inc ,Carl Novina At Dana Farber Cancer Institute ,Drug Administration ,Harvard Medical School ,Liquidia Corporation ,Davita Venture Group ,Research Triangle Park ,Dana Farber Cancer Institute ,Cobro Ventures ,Lightchain Capital ,Circle Alternative Investments ,Evans Capital ,Rivas Capital ,Willett Advisors ,Carl Novina ,Dana Farber Cancer ,Leon Wert Lamas ,Clinical Stage Asset ,United Statesfood ,Resume ,Careers ,Ew Launches Focus On Non Coding Rnas And Chronic Kidney Disease ,Iospace ,Advice ,